UNSPSC 51111613: Lenograstim

This classification denotes a recombinant protein and Immunologic adjuvant with the molecular formula C9H14N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WS4C399GB. European Medicines Agency schedules Lenograstim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02888MIG. The term LENOGRASTIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31.).

World Health Organization schedules lenograstim in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lenograstim under HS 30012010 and SITC 54162. As of Q4 2014, LENOGRASTIM remains the US FDA Preferred Term for this commodity. Lenograstim bears US NLM identifiers UMLS ID C0218640 and NCI Concept Code C49234. SMILES: N/A.

UNSPSC 51111613 Lenograstim is a Commodity code covering a recombinant human granulocyte colony-stimulating factor (G-CSF) used to treat chemotherapy-induced neutropenia and mobilize peripheral blood stem cells. State and local health agencies, primarily state Medicaid programs, state health departments, and public hospital systems, procure lenograstim through standing contracts, formulary selections, and pharmaceutical cooperative purchasing agreements. The drug is typically acquired as part of broader oncology medication portfolios or specialized pharmacy procurement initiatives that bundle multiple biopharmaceuticals. Procurement occurs through both direct RFQs to manufacturers and participation in group purchasing organization (GPO) contracts that streamline pricing and supply-chain access across multiple public entities.

The code shows limited recent state and local procurement activity in the available opportunity records, with no posted RFP, RFQ, IFB, or ITB notices explicitly naming lenograstim as a discrete line item. Lenograstim procurement at the state and local level occurs predominantly through standing-contract renewals, formulary updates, and cooperative purchasing vehicles rather than discrete solicitations, making it less visible in traditional posting channels. When state and local entities do solicit oncology pharmaceuticals openly, they typically bundle lenograstim with multiple G-CSF alternatives and supportive care agents under broader therapeutic-class RFQs. Activity is concentrated among large state Medicaid programs and academic medical center systems, particularly in regions with established cancer treatment networks, though the absence of recent standalone opportunities suggests most acquisition occurs through existing cooperative frameworks rather than newly advertised competitions.